학술논문
Application of SARS-CoV-2 Serology to Address Public Health Priorities
Document Type
article
Author
Amy C. Sherman; Teresa Smith; Yerun Zhu; Kaitlin Taibl; Jessica Howard-Anderson; Taylor Landay; Nora Pisanic; Jennifer Kleinhenz; Trevor W. Simon; Daniel Espinoza; Neena Edupuganti; Skyler Hammond; Nadine Rouphael; Huifeng Shen; Jessica K. Fairley; Srilatha Edupuganti; Jaime A. Cardona-Ospina; Alfonso J. Rodriguez-Morales; Lakshmanane Premkumar; Jens Wrammert; Rick Tarleton; Scott Fridkin; Christopher D. Heaney; Erin M. Scherer; Matthew H. Collins
Source
Frontiers in Public Health, Vol 9 (2021)
Subject
Language
English
ISSN
2296-2565
Abstract
Background: Antibodies against SARS-CoV-2 can be detected by various testing platforms, but a detailed understanding of assay performance is critical.Methods: We developed and validated a simple enzyme-linked immunosorbent assay (ELISA) to detect IgG binding to the receptor-binding domain (RBD) of SARS-CoV-2, which was then applied for surveillance. ELISA results were compared to a set of complimentary serologic assays using a large panel of clinical research samples.Results: The RBD ELISA exhibited robust performance in ROC curve analysis (AUC> 0.99; Se = 89%, Sp = 99.3%). Antibodies were detected in 23/353 (6.5%) healthcare workers, 6/9 RT-PCR-confirmed mild COVID-19 cases, and 0/30 non-COVID-19 cases from an ambulatory site. RBD ELISA showed a positive correlation with neutralizing activity (p =